NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of NextCure (NASDAQ:NXTC) in a research note released on Monday,Benzinga reports. The firm currently has a $3.00 price objective on the stock.

NextCure Price Performance

NXTC stock opened at $0.64 on Monday. The stock has a market capitalization of $17.94 million, a price-to-earnings ratio of -0.31 and a beta of 0.71. The business’s fifty day moving average price is $0.77 and its two-hundred day moving average price is $1.08. NextCure has a fifty-two week low of $0.64 and a fifty-two week high of $2.57.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). Research analysts expect that NextCure will post -1.87 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in NextCure by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock worth $307,000 after buying an additional 27,812 shares during the period. Peapod Lane Capital LLC acquired a new stake in shares of NextCure during the 4th quarter worth $311,000. Citadel Advisors LLC grew its holdings in shares of NextCure by 40.6% during the 4th quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock worth $61,000 after purchasing an additional 22,724 shares in the last quarter. Tang Capital Management LLC grew its holdings in shares of NextCure by 7.3% during the 4th quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock worth $540,000 after purchasing an additional 47,614 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of NextCure by 27.9% during the 4th quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock worth $400,000 after purchasing an additional 113,300 shares in the last quarter. Institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.